Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors

被引:139
作者
Furgeson, DY [1 ]
Dreher, MR [1 ]
Chilkoti, A [1 ]
机构
[1] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA
关键词
elastin-like polypeptide; thermoresponsive; hydrazone; doxorubicin; drug delivery;
D O I
10.1016/j.jconrel.2005.10.006
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A thermoresponsive, genetically engineered, elastin-like polypeptide (ELP) containing a C-terminal cysteine residue was synthesized and purified by inverse transition cycling (ITC) and conjugated to doxorubicin (Dox) molecules through four different pH-sensitive, maleimide-activated, hydrazone linkers. The efficiency of Dox activation, conjugation ratios to ELP and biophysical characterization-hydrodynamic radius (R-h) and the temperature transition kinetics-of the ELP-Dox conjugates and pH-mediated release of Dox were quantified in this study. Conjugation ratios of the maleimide-activated Dox to the thiol group of a unique cysteine in the ELP were close to unity. The R-h of the conjugate increased as the linker length between the ELP backbone and Dox was increased. The linker structure and length had little effect on the T-t of the ELP-Dox conjugates, as all conjugates exhibited T-t's that were similar to the native ELP. However, the ELP-Dox conjugates with longer linkers exhibited slower transition kinetics compared to the ELP-Dox conjugates with shorter linkers. The highest release of the ELP-Dox conjugate by cleavage of the hydrazone bond at pH 4 was nearly 80% over 72 h and was exhibited by the conjugate with the shortest linker. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:362 / 369
页数:8
相关论文
共 32 条
[1]  
DIMARCO A, 1969, CANCER CHEMOTH REP 1, V53, P33
[2]   Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy [J].
Dreher, MR ;
Raucher, D ;
Balu, N ;
Colvin, OM ;
Ludeman, SM ;
Chilkoti, A .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :31-43
[3]   A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin [J].
Gewirtz, DA .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (07) :727-741
[4]   MOLECULAR MODEL FOR ELASTIN STRUCTURE AND FUNCTION [J].
GRAY, WR ;
SANDBERG, LB ;
FOSTER, JA .
NATURE, 1973, 246 (5434) :461-466
[5]   HYPER EXPRESSION OF AN ENVIRONMENTALLY FRIENDLY SYNTHETIC-POLYMER GENE [J].
GUDA, C ;
ZHANG, X ;
MCPHERSON, DT ;
XU, J ;
CHERRY, JH ;
URRY, DW ;
DANIELL, H .
BIOTECHNOLOGY LETTERS, 1995, 17 (07) :745-750
[6]  
HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ
[7]   Transferrin conjugates of doxorubicin: Synthesis, characterization, cellular uptake, and in vitro efficacy [J].
Kratz, F ;
Beyer, U ;
Roth, T ;
Tarasova, N ;
Collery, P ;
Lechenault, F ;
Cazabat, A ;
Schumacher, P ;
Unger, C ;
Falken, U .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (03) :338-346
[8]   Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives.: Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound [J].
Kratz, F ;
Warnecke, A ;
Scheuermann, K ;
Stockmar, C ;
Schwab, J ;
Lazar, P ;
Drückes, P ;
Esser, N ;
Drevs, J ;
Rognan, D ;
Bissantz, C ;
Hinderling, C ;
Folkers, G ;
Fichtner, I ;
Unger, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (25) :5523-5533
[9]   Drug-polymer conjugates containing acid-cleavable bonds [J].
Kratz, F ;
Beyer, U ;
Schütte, MT .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1999, 16 (03) :245-288
[10]   A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy [J].
Kratz, F ;
Müller-Driver, R ;
Hofmann, I ;
Drevs, J ;
Unger, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (07) :1253-1256